|
Hutchmed China Ltd on Monday said several of its oncology medicines will continue to be reimbursed under China’s national insurance scheme next year, while one of its newer cancer drugs has secured a place on the country’s first-ever commercial insurance drug list. Hutchmed said it has renewed its contract with the China National Healthcare Security Administration, ensuring that the updated national reimbursement drug list, effective January 1, will continue to cover three of its products: Elunate, Orpathys and Sulanda. Elunate, developed with Eli Lilly & Co, has been renewed for metastatic colorectal cancer and added for advanced endometrial cancer in combination with Tyvyt. Orpathys, partnered with AstraZeneca PLC, remains reimbursed for MET exon 14 skipping non-small cell lung cancer, while Sulanda continues to be covered for pancreatic and non-pancreatic neuroendocrine tumours. The company also said Tazverik, its EZH2 inhibitor for relapsed or refractory follicular lymphoma, will be included in the first edition of China’s new commercial insurance drug list, which targets high-innovation therapies that fall outside basic medical insurance. Hutchmed said the new list forms part of China’s emerging multi-level insurance framework and will allow Tazverik to be reimbursed through commercial health plans. Shares in Hutchmed China were up 2.1% at 217.40 pence in London on Monday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
